Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) currently lacks effective targeted therapeutic approaches. Although isoliquiritigenin (ISL) exhibits hepatoprotective effects, its precise molecular target remains unclear. This study aims to identify the potential molecular target and mechanism of ISL in MASLD. Methods: HFD-induced MASLD mice were treated with ISL, while palmitic acid (PA)-challenged HepG2 cells were used as an in vitro lipotoxicity model. RNA sequencing (RNA-seq), molecular docking, cellular thermal shift assay (CETSA), and S100A8 overexpression plasmids were employed to investigate the underlying molecular mechanism. Results: In vivo , ISL significantly reduced serum transaminases, hepatic lipid accumulation, and fibrosis. RNA-seq showed that ISL mainly regulated ferroptosis and the mitogen-activated protein kinase (MAPK) pathway, with S100A8 identified as an important candidate regulatory target. Molecular docking and CETSA assays point toward a possible direct interaction between ISL and S100A8, implying that ISL could improve the thermal stability of S100A8. In vitro , ISL reversed PA-triggered lipid accumulation, reduced lipid peroxidation as indicated by MDA levels, restored glutathione peroxidase 4 (GPX4) expression, inhibited acyl-CoA synthetase long-chain family member 4 (ACSL4) expression, and suppressed phosphorylation of p38 and p44/42 MAPK. ISL interacted with S100A8 and modulated S100A8-associated MAPK signaling and ferroptosis, thereby alleviating lipotoxic liver injury and fibrosis. Conclusion: These findings support S100A8 as an important mediator of ISL's protective effects and provide a mechanistic basis for its potential application in MASLD
Ying Zhang, Bing-Qian Li, Ying-Nan Song et al.· Traditional Medicine Researc...· 0 citations
Background Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common malignancy globally, with tumor uncontrolled angiogenesis being major causes of therapeutic failure and patient death. Isoalantolactone (IATL), a natural compound, exhibits antioxidant, anti-inflammatory, anti-proliferative, and anti-tumor properties. However, its role in inhibiting tumor angiogenesis in pancreatic cancer and the underlying mechanisms remain unclear. This study aims to investigate the anti-angiogenic effects of IATL in PDAC and elucidate the associated molecular pathways. Methods In vitro experiments were performed using PDAC cell lines (Panc02, PANC-1, and SW 1990) and HUVECs. In vivo studies were conducted using an orthotopic pancreatic cancer model in C57BL/6 mice. Cell viability, wound-healing, tube formation, in vivo imaging system analysis, laser speckle contrast imaging, immunohistochemistry, immunofluorescence, RT-qPCR, ELISA, and Western blot assays were used to evaluate the effects of IATL on tumor growth, angiogenesis, and inflammatory responses. Molecular docking and cellular thermal shift assay were performed to assess the interaction between IATL and NLRP3. Results IATL significantly inhibited the proliferation and migration of Panc02, PANC-1, and SW1990 cells. In the orthotopic pancreatic cancer model, IATL dose-dependently suppressed tumor growth, as evidenced by reduced IVIS fluorescence signals and tumor volume. IATL also markedly inhibited angiogenesis, as shown by reduced HUVECs migration and tube formation, decreased tumor blood perfusion detected by laser speckle imaging, and downregulated CD34 and VEGFA expression both in vivo and in vitro. Network pharmacology, molecular docking, and cellular thermal shift assay identified NLRP3 as a direct target of IATL. Mechanistically, IATL suppressed NLRP3 inflammasome activation, reduced ASC speck formation, inhibited the NLRP3/IL-1β signaling axis, and decreased the expression of inflammatory cytokines, including IL-6, TNF-α, IL-1β, and IL-18. NLRP3 knockdown mimicked the effects of IATL, whereas NLRP3 overexpression partially reversed its anti-tumor, anti-angiogenic, and anti-inflammatory effects, further supporting the target specificity of IATL. Conclusion IATL functions as a novel NLRP3 pathway inhibitor, suppressing angiogenesis through anti-inflammatory mechanisms, thereby effectively inhibiting PDAC progression. These findings suggest that IATL holds potential as a therapeutic agent for pancreatic cancer.
Ying Zhang, Changquan Liu, Shengjiang Liu et al.· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
